纵横研报
Ticker Detail

600645.SHG

¥18.94+0.00% 中源协和 Biotechnology
00Reports China 医疗健康
Vcanbio Cell & Gene Engineering Corp Ltd
医疗健康 · 生物科技

Vcanbio Cell & Gene Engineering Corp., Ltd, together with its subsidiaries, engages in the preparation and storage of cell detection tests in the People's Republic of China. It offers cell test preparation and storage services for umbilical cord blood hematopoietic stem cells, umbilical cord mesenchymal stem cells, placental pluripotent stem cells, immune cells, adipose stem cells, and dental stem cells. The company also provides genetic testing services related to non-invasive prenatal genetic testing during pregnancy, genetic testing for drug safety guidance, disease genetic testing, and disease susceptibility testing for children and adults; and in vitro diagnostic raw materials, such as monoclonal antibodies and polyclonal antibody products. In addition, it is involved in the research, development, production, and sales of biological genes, proteins, antibodies, pharmaceutical intermediates, and synthetic agents; and in vitro diagnostic reagents and medical devices. The company was founded in 1992 and is based in Tianjin, the People's Republic of China.

MARKET 市值 8.50B CNY PE 75.7x Fwd 196.1x 52W ¥16.24 – ¥32.99 EODHD · Q 2026-03-31 · 同步 2026-07-14
QUALITY PEG 0.62 营收 YoY -9.5% ROE 2.7% 营业利润率 9.5% 净利润率 7.7%

暂无相关研报

数据库中已收录该标的的基本面数据,可发起一份定制研报。

CUSTOM RESEARCH · 定制研报 没找到完全契合的标的?让我们替你做一份。 告诉我们你关心的标的与偏好,1 个工作日内在站内上线。 开始定制